Sten Scheibye was born on 3 October 1951 and is a Danish national. He holds an MSc in Chemistry and Physics from 1978 and a PhD in Organic Chemistry from 1981, both from the University of Aarhus, Denmark. In 1983, he obtained a BComm from Copenhagen Business School.
From 1995 to 2008, Sten Scheibye was President and CEO of Coloplast A/S, Denmark. Before joining Coloplast in 1993, he served as Senior Vice President, Sales & Marketing in Leo Pharma A/S, Denmark. He joined this company in 1981.
Sten Scheibye is Chairman of the Board of Directors of the Novo Nordisk Foundation, the Danish Industry Foundation, the Rich. Müller Foundation, RMIG Rich. Müller A/S and Knud Højgaard's Foundation.
Göran Ando was born on 6 March 1949 and is a Swedish national. Dr Ando is a specialist in General Medicine and a Founding Fellow of the American College of Rheumatology in the US. Dr Ando is former Executive Vice President and President of Research & Development of Pharmacia Corporation, which was acquired by Pfizer Inc. in 2003.
In April 2003, he was appointed CEO of the Celltech Group PLC in the UK until its acquisition in 2004 by UCB.
Göran Ando is Chairman of the Board of Directors of Novo Nordisk A/S and Symphogen A/S, and a member of the Board of Directors of Molecular Partners, EUSA Pharma and ICMEC.
Göran Ando serves as a Senior Advisor to EW Healthcare Partners.
Jeppe Christiansen was born on 25 November 1959 and is a Danish national. He holds an MSc in Economics from the University of Copenhagen. Since 2004, Jeppe Christiansen has served as CEO of Maj Invest A/S, of which he is also a co-founder.
From 1986 to 1988, Jeppe Christiansen worked as an economist in Sparekassen SDS. He came to LD Pensions in 1988 where he became Head of Fund Management and later, as Executive Vice President, responsible for investments. From 1998 to 2004, Jeppe Christiansen worked as a Director in Danske Bank, responsible for international equity investments and corporate clients.
Jeppe Christiansen is Vice Chairman of Novo Nordisk A/S, Chairman of the board of Haldor Topsøe A/S and Emlika ApS, and member of the board of directors of Kirkbi A/S, Symphogen A/S and Det Kgl. Vajsenhus.
Steen Riisgaard was born on 22 March 1951 and is a Danish national. He holds an MSc in Microbiology from the University of Copenhagen.
Steen Riisgaard was President and CEO of Novozymes A/S from the demerger from Novo Nordisk A/S in 2000 until April 2013. He joined Novo Nordisk in 1979 in Enzymes Research & Development. In 1982, he moved to Tokyo to start up an enzymes R&D unit in the Novo Nordisk subsidiary, Novo Industri Japan Ltd. After his return to Denmark in 1985, he held a number of different positions in the company before he was promoted to Corporate Executive Vice President in 1989 -with special responsibility for the Enzyme business.
Prior to joining Novo Nordisk, he was a research fellow at Statens Serum Institut (SSI) and a research microbiologist at Foss Electric, Denmark.
Steen Riisgaard is Chairman of the Board of Directors of ALK-Abello A/S, Cowi Holding A/S, Egmont International Holding A/S, Xellia Pharmaceuticals A/S and the WWF (the World Wildlife Fund) Denmark. Furthermore, he is Vice Chairman of the Boards of the Novo Nordisk Foundation and the Villum Foundation, and serves on the Boards of Aarhus University, Corbion nv and VKR Holding.
Per Wold-Olsen was born on 6 November 1947 and is a Norwegian national. He holds an MBA in Economics Administration as well as an MBA in Management and Marketing.
Per Wold-Olsen joined Merck & Co. (MSD) in 1974. He became Managing Director of the Norwegian subsidiary in 1976 and Regional Director and Vice President of the Scandinavian region in 1986. In 1991, Per Wold-Olsen was appointed Senior Vice President for Worldwide Human Health Marketing of Merck & Co. Inc. in the US, and in 1994, he was appointed President of Human Health Europe of Merck & Co., Inc. In 1997, his region increased to include Eastern Europe, the Middle East and Africa, as well as Worldwide Human Health Marketing. In 2005, he was appointed President of the Human Health Intercontinental Region, Merck & Co. Inc. From 1994 to 2006, he was also a member of Merck's Management Committee.
Per Wold-Olsen is Chairman of the Board of Directors of GN Store Nord A/S and Medicines for Malaria Venture, and serves on the Board of Directors of Gilead Sciences Inc.
Lars Rebien Sørensen was born in 1954. He received an MSc in Forestry from the Royal Veterinary and Agricultural University, Copenhagen in 1981 and a BSc in International Economics from Copenhagen Business School in 1983.
Lars Rebien Sørensen joined Novo Nordisk Enzymes Marketing in 1982 and over the years was assigned various overseas posts, including the Middle East and the United States. In May 1994, he was appointed a member of corporate management, and in December 1994 he assumed responsibility for the healthcare business. He was appointed President and CEO of Novo Nordisk A/S in November 2000, a position he held until 31 December 2016.
Lars Rebien Sørensen is Deputy Chairman of the Carlsberg Group and a member of the Supervisory Board of Thermo Fischer Scientific Inc., United States.
In 2007, Lars Rebien Sørensen was appointed Adjunct Professor at the Faculty of Life Sciences of the University of Copenhagen.
Jean-Luc Butel was born on 8 November 1956 and is a French national. He holds a BA in International Affairs, George Washington University and an MBA in International Management, Thunderbird School of Global Management, Glendale.
Jean-Luc Butel joined Johnson & Johnson Medical in 1984 and remained until 1991. In 1991, he started working in Becton Dickinson & Company as President Japan and President, Worldwide Consumer Healthcare in USA. From 1999 to 2003, Jean-Luc Butel was President of J&J Independence Technology. He came to Medtronic in 2003, where he served as Senior Vice President and later was appointed Executive Vice President and President, International. From 2012 to 2015, Jean-Luc Butel joined Baxter International as the Corporate Vice President and President, International. Since 2015, he has been a Senior Advisor for McKinsey & Company Healthcare Systems & Services.
Jean-Luc Butel is a member of the boards of directors of Takada Pharmaceutical Co. Ltd, ETPL (A*Star), Varian Medical Systems Inc., Singapore Economic Development Board and SGInnovate.
Francis Cuss was born on 25 June 1954 and is a dual national of both the United Kingdom and the United States of America. He is a physician-scientist with the following degrees from the University of Cambridge: BA in Natural Sciences, MB, BChir, MA. He is a Fellow of Royal College of Physicians (UK) and of the Faculty of Pharmaceutical Medicine (UK).
Following spells in clinical medicine and research in the UK, Francis Cuss spent the next 31 years in the Pharmaceutical Industry, starting at Glaxo Inc., USA and UK, from 1986 to 1989, most recently as Director, Pulmonary Clinical Research. From 1989, he worked at the Schering-Plough Research Institute and held several positions in discovery and development, the latest as Senior Vice President, Early Clinical Research & Experimental Medicine. Francis Cuss joined Bristol-Myers Squibb R&D in 2003, first working as Senior Vice President, Discovery and later as Senior Vice President for all of Research, and Early Development. In 2010, he joined the company’s senior management team, and in 2013, was appointed Executive Vice President, Chief Scientific Officer of Bristol-Myers Squibb Company and head of R&D.
Francis Cuss is Vice Chair of the Board of Trustees and Vice Chair, Audit, Finance and Investment Committee, Montclair State University, NJ, United States.